Financial reports
10-K/A
2023 FY
Annual report (amended)
22 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
10-K
2022 FY
Annual report
16 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
16 Mar 22
Current reports
8-K
Unregistered Sales of Equity Securities
18 Apr 24
8-K
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKEĀ® for Phenylketonuria
22 Mar 24
8-K
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
14 Mar 24
8-K
Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation
21 Feb 24
8-K
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
2 Feb 24
8-K
Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results
9 Nov 23
8-K
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
4 Oct 23
8-K
Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results
10 Aug 23
8-K
Termination of a Material Definitive Agreement
5 Jul 23
8-K
Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol Injection
28 Jun 23
Registration and prospectus
S-8
Registration of securities for employees
26 Mar 24
S-3
Shelf registration
7 Apr 23
S-8
Registration of securities for employees
20 Mar 23
424B3
Prospectus supplement
9 Apr 21
424B3
Prospectus supplement
7 Apr 21
424B5
Prospectus supplement for primary offering
15 Oct 20
424B5
Prospectus supplement for primary offering
13 Oct 20
S-3
Shelf registration
31 Jul 20
D
$7.5M in equity, sold $7.5M, 2 investors
8 Apr 20
424B5
Prospectus supplement for primary offering
30 Mar 20
Other
EFFECT
Notice of effectiveness
3 May 23
CORRESP
Correspondence with SEC
1 May 23
UPLOAD
Letter from SEC
12 Apr 23
EFFECT
Notice of effectiveness
26 Aug 20
CORRESP
Correspondence with SEC
24 Aug 20
UPLOAD
Letter from SEC
4 Aug 20
UPLOAD
Letter from SEC
27 May 20
CORRESP
Correspondence with SEC
15 May 20
UPLOAD
Letter from SEC
5 May 20
EFFECT
Notice of effectiveness
17 Dec 19
Ownership